Close Menu
    Facebook X (Twitter) Instagram
    SciTechDaily
    • Biology
    • Chemistry
    • Earth
    • Health
    • Physics
    • Science
    • Space
    • Technology
    Facebook X (Twitter) Pinterest YouTube RSS
    SciTechDaily
    Home»Health»Unexpected Discovery: Vascular Defects Appear to Underlie the Progression of Parkinson’s Disease
    Health

    Unexpected Discovery: Vascular Defects Appear to Underlie the Progression of Parkinson’s Disease

    By Georgetown University Medical CenterNovember 12, 20212 Comments5 Mins Read
    Facebook Twitter Pinterest Telegram LinkedIn WhatsApp Email Reddit
    Share
    Facebook Twitter LinkedIn Pinterest Telegram Email Reddit
    MRI Brain Arteries
    In some Parkinson’s patients, the blood-brain barrier malfunctions, preventing toxins from leaving the brain and nutrients like glucose from entering. Additionally, the barrier allows inflammatory cells and molecules from the body to enter, potentially damaging the brain.

    Study links Parkinson’s to blood-brain barrier defects.

    In an unexpected discovery, Georgetown University Medical Center researchers have identified what appears to be a significant vascular defect in patients with moderately severe Parkinson’s disease. The finding could help explain an earlier outcome of the same study, in which the drug nilotinib was able to halt motor and non-motor (cognition and quality of life) decline in the long term.

    The researchers say their finding, detailed in a study published today (November 12, 2021) in Neurology Genetics, suggests that blood vessel walls called the blood-brain barrier, which normally act as a crucial filter to protect the brain against toxins as well as allow passage of nutrients to nourish it, doesn’t work correctly in some Parkinson’s patients: it prohibits toxins from leaving the brain and inhibits nutrients such as glucose from entering. Perhaps even more damaging, the dysfunctional barrier allows inflammatory cells and molecules from the body to enter and damage the brain.

    Genomics Provides a New Therapeutic Target

    The research, the first longitudinal study to use such advanced genomics, now provides investigators with a new target for therapeutic intervention in Parkinson’s disease, says the study’s senior author, Charbel Moussa, MBBS, PhD, director of the Medical Center’s Translational Neurotherapeutics Program.

    The new discovery comes from the second part of a Phase II clinical trial that featured next-generation whole genome sequencing of the cerebrospinal fluid of 75 Parkinson’s patients, before and after treatment with a repurposed leukemia drug, nilotinib, or placebo.

    This study lasted 27 months; the initial trial was double-blinded and patients were randomized to either placebo, or 150mgs or 300mgs nilotinib for 12 months. The patients had severe Parkinson’s disease; all treated with optimal standard of care and many (30%) had also used the most sophisticated treatments possible, such as deep brain stimulation. The second part of the study employed an adaptive design and all participants had a 3-month drug washout period before re-randomization to either 150mgs or 300mgs for an additional 12 months. After 27 months, nilotinib was found to be safe, and patients who received nilotinib showed a dose-dependent increase of dopamine, the chemical lost as a result of neuronal destruction.

    “It appeared nilotinib halted motor and non-motor decline in the patients taking the 300mgs higher dose,” says Moussa. The clinical outcomes of this study was published in Movement Disorders in March 2021.

    The current part of the study just published, examined the cerebrospinal fluid of patients via epigenomics, which is a systematic analysis of the global state of gene expression, in correlation with continuing clinical outcomes. The new analysis helps explain the clinical findings.

    DDR1 Inhibition Restores Blood-Brain Barrier Function

    Nilotinib inactivated a protein (DDR1) that was destroying the ability of the blood-brain barrier to function properly. When DDR1 was inhibited, normal transport of molecules in and out of the brain filter resumed, and inflammation declined to the point that dopamine, the neurotransmitter depleted by the disease process, was being produced again.

    Moussa and his team have long been working on the effects that nilotinib (Tasigna) may have on neurodegeneration, including Alzheimer’s and Parkinson’s diseases. The drug was approved in 2007 for chronic myelogenous leukemia (CML), but Moussa reasoned that its mechanism of action may help the brain destroy toxins that develop in the brains of patients with neurodegenerative disorders.

    Repairing the Brain’s “Garbage Disposal” and Filter

    “Not only does nilotinib flip on the brain’s garbage disposal system to eliminate bad toxic proteins, but it appears to also repair the blood-brain barrier to allow this toxic waste to leave the brain and to allow nutrients in,” Moussa explains. “Parkinson’s disease is generally believed to involve mitochondrial or energy deficits that can be caused by environmental toxins or by toxic protein accumulation; it has never been identified as a vascular disease.”

    “To our knowledge, this is the first study to show that the body’s blood-brain barrier potentially offers a target for the treatment for Parkinson’s disease,” Moussa says. “Much work remains to be done, but just knowing that a patient’s brain vascular system is playing a significant role in the progression of the disease is a very promising discovery.”

    Reference: “CSF MicroRNAs Reveal Impairment of Angiogenesis and Autophagy in Parkinson Disease” by Alan J. Fowler, Jaeil Ahn, Michaeline Hebron, Timothy Chiu, Reem Ayoub, Sanjana Mulki, Habtom Ressom, Yasar Torres-Yaghi, Barbara Wilmarth, Fernando L. Pagan and Charbel Moussa, 12 November 2021, Neurology Genetics.
    DOI: 10.1212/NXG.0000000000000633

    In addition to Moussa, authors on the report include Alan J Fowler, MS; Jaeil Ahn, PhD; Michaeline Hebron, MS; Timothy Chiu; Reem Ayoub; Sanjana Mulki, MS; Habtom Ressom, PhD; Yasar Torres-Yaghi, MD; Barbara Wilmarth, NP; and Fernando L Pagan, MD.

    Never miss a breakthrough: Join the SciTechDaily newsletter.
    Follow us on Google and Google News.

    Brain Georgetown University Neurology Parkinson's Disease Popular
    Share. Facebook Twitter Pinterest LinkedIn Email Reddit

    Related Articles

    Why Are Men Twice As Likely To Develop Parkinson’s? Scientists Discover a Hidden Clue in the Brain

    Scientists Uncover Promising New Strategy To Stop Parkinson’s in Its Tracks

    Scientists May Have Found the True Source of Parkinson’s Disease

    Widely Used Farm Chemical May More Than Double Parkinson’s Disease Risk

    How a Simple Worm May Hold the Key to Stopping Parkinson’s and Alzheimer’s

    Scientists Propose “Radically Different” New Way of Looking at Parkinson’s Disease

    New Hope for Treatment of Parkinson’s Disease: Designer Neurons

    Deep Brain Stimulation Research Shows Promising Results for Treating Parkinson’s Disease

    Identifying “The Terrorist Inside My Husband’s Brain” – Living Brain Imaging Can Clearly Differentiate Between Types of Dementia

    2 Comments

    1. Brian Anthony on November 28, 2021 12:54 pm

      The article on the GUMC research into the use of Nilotinib in the treatment of Parkinson’s is most encouraging.
      Many thanks.

      Reply
    2. Bink on March 23, 2025 6:24 pm

      I would like to know if most patients were terrible at hydrating sufficiently throughout their youth…

      Reply
    Leave A Reply Cancel Reply

    • Facebook
    • Twitter
    • Pinterest
    • YouTube

    Don't Miss a Discovery

    Subscribe for the Latest in Science & Tech!

    Trending News

    Scientists Discover Crows Make Decisions Twice As Fast as Humans

    Animal vs. Plant Protein: New Study Reveals Unexpected Testosterone Differences

    A Black Hole Could Split in Two, According to a Surprising New Theory

    Scientists Sound the Alarm As Colorectal Cancer Reverses a 20-Year Decline

    A Devastating Disease Is Threatening the World’s Chocolate Supply – but Scientists May Have Found the Answer

    NASA’s Voyager 1 Is About to Become the First Spacecraft One Light-Day From Earth

    A Woman Who Lived 30,000 Years Ago Is Changing What We Know About Ice Age Europe

    A Rare Radioactive Element Reveals a Hidden Secret About the Heaviest Atoms

    Follow SciTechDaily
    • Facebook
    • Twitter
    • YouTube
    • Pinterest
    • Newsletter
    • RSS
    SciTech News
    • Biology News
    • Chemistry News
    • Earth News
    • Health News
    • Physics News
    • Science News
    • Space News
    • Technology News
    Recent Posts
    • Scientists Discover Greenland’s Ice Sheet Once Retreated 60 Miles
    • Researchers Recover DNA from 7,000-Year-Old Leather, Revealing a Link to Goats Alive Today
    • Scientists Discover Climate Change May Have Stopped Earth’s Next Ice Age
    • Strange Materials Make Waves Behave in Ways That Defy Expectations
    • Quantum Discovery Reveals Why More Powerful Lasers Can Actually Slow Atoms Down
    Copyright © 1998 - 2026 SciTechDaily. All Rights Reserved.
    • Science News
    • About
    • Contact
    • Editorial Board
    • Privacy Policy
    • Terms of Use

    Type above and press Enter to search. Press Esc to cancel.